Tag:
IPO
Latest Headlines
Latest Headlines
NanoString files for $86M IPO
Fresh off the launch its gene-expression cancer diagnostic, Seattle's NanoString is plotting an IPO worth up to $86.3 million, the company disclosed Monday.
PRA winds up for IPO
Perhaps encouraged by the success of its North Carolina neighbor Quintiles, PRA is making moves toward an IPO of its own, filing a confidential draft registration form with the SEC.
Quintiles prices $790M IPO
Quintiles has finally affixed a price tag to its long-held plans to go public, plotting to raise about $790 million and pay down its outstanding debt.
Cancer Genetics bags $6.9M in over-allotted IPO
After scaling back its IPO price by about 85%, diagnostics outfit Cancer Genetics has some good news to report, pulling in $6.9 million once its under-writers exercised their over-allotment option.
Cancer Genetics finally going public at slashed price
Cancer Genetics was looking at a $41.9 million IPO when first it decided to go public last year, but now the company is seeking just $6 million in its initial offering, which it expects to close next week.
Biotech Chimerix reveals ex-Pharmasset recruit after unveiling $85M IPO plan
As the biotech advances its lead antiviral drug to Phase III development, Chimerix has tapped a veteran of one of the most high-profile pharma R&D programs in the world.
Cancer Genetics scales back IPO yet again, seeks $14.3M
Cancer Genetics' target IPO price keeps on falling, from about to $41.9 million back in May to a hopeful $14.3 million now.
Buzz: Pharma software outfit Veeva seeks IPO
After besting rivals such as Oracle in the pharma market, Veeva Systems aims to complete an initial public offering that values the cloud software provider at $2 billion, sources told Bloomberg .
Moody's says Quintiles is worth $4B, but IPO price remains mystery
Last week's big news that Quintiles is finally going public left one burning question: How much will the company raise in its IPO?
AutoGenomics aborts second try at IPO
AutoGenomics has given up on its second IPO less than 5 years after not having all of its paperwork together in time for a crucial regulatory filing deadline. But the California-based molecular diagnostics developer wants to make a third attempt in the second quarter of 2013.
